EA202190306A1 - COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR - Google Patents

COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR

Info

Publication number
EA202190306A1
EA202190306A1 EA202190306A EA202190306A EA202190306A1 EA 202190306 A1 EA202190306 A1 EA 202190306A1 EA 202190306 A EA202190306 A EA 202190306A EA 202190306 A EA202190306 A EA 202190306A EA 202190306 A1 EA202190306 A1 EA 202190306A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combinations
capsid assembly
methods including
assembly inhibitor
including capsid
Prior art date
Application number
EA202190306A
Other languages
Russian (ru)
Inventor
Джордж Хартман
Освальдо Флорес
Клаус Клумпп
Ман Лу Лам
Ян Мартин Берк
Original Assignee
Новира Терапьютикс, Инк.
Янссен Сайенсиз Айрлэнд Юси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новира Терапьютикс, Инк., Янссен Сайенсиз Айрлэнд Юси filed Critical Новира Терапьютикс, Инк.
Publication of EA202190306A1 publication Critical patent/EA202190306A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment

Abstract

Изобретение относится к композициям ингибиторов сборки капсида и способам их применения в лечении вирусной инфекции гепатита B.The invention relates to compositions of capsid assembly inhibitors and methods of their use in the treatment of hepatitis B viral infection.

EA202190306A 2016-11-11 2017-04-14 COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR EA202190306A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662421035P 2016-11-11 2016-11-11

Publications (1)

Publication Number Publication Date
EA202190306A1 true EA202190306A1 (en) 2021-08-17

Family

ID=65950021

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201892348A EA037576B1 (en) 2016-11-11 2017-04-14 Combinations and methods comprising a capsid assembly inhibitor
EA202190306A EA202190306A1 (en) 2016-11-11 2017-04-14 COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201892348A EA037576B1 (en) 2016-11-11 2017-04-14 Combinations and methods comprising a capsid assembly inhibitor

Country Status (1)

Country Link
EA (2) EA037576B1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026368B1 (en) * 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Hepatitis b antiviral agents
CN105209031A (en) * 2012-12-27 2015-12-30 德雷克塞尔大学 Novel antiviral agents against HBV infection
JO3603B1 (en) * 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) * 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) * 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN105980378B (en) * 2014-02-06 2019-09-27 爱尔兰詹森科学公司 Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
US9400280B2 (en) * 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections

Also Published As

Publication number Publication date
EA037576B1 (en) 2021-04-15
EA201892348A1 (en) 2019-03-29

Similar Documents

Publication Publication Date Title
EA201691726A1 (en) NEW 6-CONDENSED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
MX2020011808A (en) Combinations and methods comprising a capsid assembly inhibitor.
EA201791460A1 (en) N4-HYDROXYCYTIDINE AND RELATED DERIVATIVES AND OPTIONS FOR ANTI-VIRUS APPLICATION
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
EA201792069A1 (en) DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B
EA201691440A1 (en) AZEPAN DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
MX2018005230A (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon.
EA201790630A1 (en) METHODS OF OBTAINING RIBOSIDS
EA201790413A1 (en) ANTIBODIES AGAINST TIGIT
EA201690979A1 (en) AZEPAN DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA201592126A1 (en) 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
MA40547A (en) Indoles for use in influenza virus infection
EA202091114A1 (en) NEW HIGHLY ACTIVE PYRAZOLOPIPERIDINE-SUBSTITUTED INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
EA201890810A1 (en) COMPOUNDS EFFECTIVE FOR THE TREATMENT OF HEPATOTOXICITY AND LIVER STEATOSIS AND THEIR APPLICATION
EA201891975A1 (en) TIAZOLID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
EA201692358A1 (en) IZOINDOLIN DERIVATIVES FOR USE IN THE TREATMENT OF VIRAL INFECTION
EA201692034A1 (en) NEW MACROCYCLIC COMPOUNDS
EA201792580A1 (en) IDO INHIBITORS
EA201790517A1 (en) METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST PHILOVIRUS INFECTION
EA201690594A1 (en) COMPOSITION FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ATAZANAVIR AND COBICISTAT
EA202090693A1 (en) NEW MEK INHIBITOR FOR TREATMENT OF VIRAL AND BACTERIAL INFECTIONS
JOP20190214A1 (en) subbstituted Dihydroindene-4-Carboxamides and Analogs Thereof, and Methods Using Same
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201790771A1 (en) PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION FOR THE TREATMENT OF HEPATITIS C